We are live on ! Find out more
GCVRZ

Sanofi Contingent Value Rights
GCVRZ

Delisted

GCVRZ was delisted on the 3rd of March, 2020.

Back to rankings

104 hedge funds and large institutions have $80.8M invested in Sanofi Contingent Value Rights in 2019 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 13 increasing their positions, 18 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

18% more capital invested

Capital invested by funds: $68.8M → $80.8M (+$12.1M)

11% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 9

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

1% less funds holding

Funds holding: 105 → 104 (-1)

28% less repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 18

Holders
104
Holders Change
-1
Holders Change %
-0.95%
% of All Funds
2.26%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
10
Increased
13
Reduced
18
Closed
9
Calls
$15.2M
Puts
–
Net Calls
+$15.2M
Net Calls Change
-$566K

Top Buyers

Rank Fund Capital Flow
1
SCM
Stonehill Capital Management
New York
+$2.08M
2
BHMP
Bardin Hill Management Partners
New York
+$1.12M
3
NGA
New Generation Advisors
Massachusetts
+$844K
4
UOC
UBS O'Connor
Illinois
+$580K
5
BMO
Beck Mack & Oliver
New York
+$147K

Top Sellers

Rank Fund Capital Flow
1
HCM
Highbridge Capital Management
New York
-$2.89M
2
TGHSA
TPG Group Holdings (SBS) Advisors
Texas
-$499K
3
CL
CSS LLC
Illinois
-$56.6K
4
Citadel Advisors
Citadel Advisors
Florida
-$43.6K
5
Wells Fargo
Wells Fargo
California
-$25.2K
Name Holding Trade Value Shares
Change 		Change in
Stake
YCM
26
Yakira Capital Management
Connecticut
$81K – – –
Citadel Advisors
27
Citadel Advisors
Florida
$70K -$43.6K -87,250 -39%
Wells Fargo
28
Wells Fargo
California
$56K -$25.2K -50,400 -32%
UBS Group
29
UBS Group
Switzerland
$40K +$4.63K +9,272 +14%
AL
30
Arnhold LLC
New York
$33K – – –
GI
31
GAMCO Investors
Connecticut
$32K – – –
Royal London Asset Management
32
Royal London Asset Management
United Kingdom
$23K – – –
ZIG
33
Zuckerman Investment Group
Illinois
$22K -$97 -195 -0.5%
WVP
34
Worth Venture Partners
New Jersey
$15K – – –
Morgan Stanley
35
Morgan Stanley
New York
$15K +$11 +22 +0.1%
JCI
36
Jet Capital Investors
New York
$15K +$14.2K +28,523 New
Ameriprise
37
Ameriprise
Minnesota
$13K -$552 -1,105 -4%
SDWMA
38
Schneider Downs Wealth Management Advisors
Pennsylvania
$13K – – –
Commonwealth Equity Services
39
Commonwealth Equity Services
Massachusetts
$11K +$14 +28 +0.1%
Bank of America
40
Bank of America
North Carolina
$10K -$35 -70 -0.3%
LPL Financial
41
LPL Financial
California
$9K -$108 -216 -1%
TSS
42
Two Sigma Securities
New York
$8K -$6.36K -12,738 -44%
CHAM
43
Clear Harbor Asset Management
Connecticut
$8K – – –
HKAM
44
Horizon Kinetics Asset Management
New York
$8K – – –
MC
45
Moors & Cabot
Massachusetts
$8K – – –
RWP
46
RWA Wealth Partners
Massachusetts
$8K – – –
William Blair & Company
47
William Blair & Company
Illinois
$7K -$175 -350 -2%
FHA
48
Flagship Harbor Advisors
Massachusetts
$7K – – –
EAM
49
Erste Asset Management
Austria
$6.24K – – –
BIA
50
Biondo Investment Advisors
Pennsylvania
$6K -$911 -1,825 -14%
1
2
3 4

GCVRZ Hedge Fund Activity: Q2 2019 in Review

104 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Sanofi Contingent Value Rights (GCVRZ) for Q2 2019, worth a combined $80.8M — up 18% from $68.8M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new GCVRZ positions and 9 closed out — a net gain of 1 holder — while 13 added to existing stakes and 18 trimmed.

The largest buyer was Stonehill Capital Management, adding an estimated $2.08M. The largest seller was Highbridge Capital Management, cutting an estimated $2.89M.

  • 104 institutional investors held Sanofi Contingent Value Rights (GCVRZ) as of Q2 2019, down from 105 in Q1 2019.
  • Funds reported $80.8M of Sanofi Contingent Value Rights stock for Q2 2019, up 18% quarter-over-quarter.
  • 10 funds opened new Sanofi Contingent Value Rights positions in Q2 2019 and 9 closed out, a net change of +1 holder.
  • The largest Sanofi Contingent Value Rights buyer in Q2 2019 was Stonehill Capital Management, an estimated $2.08M added.
  • The largest Sanofi Contingent Value Rights seller in Q2 2019 was Highbridge Capital Management, an estimated $2.89M sold.

Based on aggregated 13F filings for Q2 2019.